Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM001 long-term withdrawal study in Alagille syndrome
2013-005373-43Phase 2Completed
- Sponsor
- Lumena Pharmaceuticals
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of maralixibat in Alagille syndrome (ALGS) (3 arms), sponsored by Lumena Pharmaceuticals. Primary endpoint: Mean change in serum bile acid levels during withdrawal period in responders. Started May 2014; status: completed.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on 2013-005373-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005373-43.